Moderna gains HHS backing for developing mRNA-based pandemic influenza vaccines, advancing clinical studies for up to five subtypes. Get Pro-Level Earnings Insights Before the Market Moves Tuesday ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of $38.00. Terence Flynn’s rating is based ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near ...

Moderna has big plans for the next few years. Those plans will take longer than three years to pay off in full. Don't get fixated on the programs that will deliver immediate revenue. By early 2028 ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $26.01. According to ...

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Pfizer slashed its production targets for its ... In a separate announcement, rival vaccine firm Moderna said it expected to have between 100 and 125 million doses available globally in the ...

According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month, however, that it has ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

U.S. drugmaker Pfizer PFE.N is going “all in” to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...